Kiran Mazumdar-Shaw's Immuneel Therapeutics Secures $12 Million in Latest Series B Funding Round

Kiran Mazumdar-Shaw's Immuneel Therapeutics secured $12 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Kiran Mazumdar-Shaw's Immuneel Therapeutics Raises $12 million in Funding

Kiran Mazumdar-Shaw's Immuneel Therapeutics is a Bengaluru-based Digital Health company focused on scale CAR-T therapies - The HinduBusinessLine.

Investors Behind the Funding

The round was backed by a mix of new, </strong>, Singularity AMC, Rainmatter by zerodha, several high-net-worth individuals. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Kiran Mazumdar-Shaw's Immuneel Therapeutics operates in Healthcare & Life Sciences. Kiran Mazumdar-Shaw's Immuneel Therapeutics's Series B round shows investors are still backing digital health platforms with real scale narratives. At $12M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

scale CAR-T therapies - The HinduBusinessLine

Looking Ahead

Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 Cr in Series B funding

Source reference: original announcement/article.